Papers: 10.1186/s12885-019-5507-6

https://doi.org/10.1186/s12885-019-5507-6

Comparative survival benefit of currently licensed second or third line treatments for epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) negative advanced or metastatic non-small cell lung cancer: a systematic review and secondary analysis of trials

Cited by: 7
Author(s): Martin Connock, Xavier Armoiry, Alexander Tsertsvadze, G. J. Melendez‐Torres, Pamela Royle, Lazaros Andronis, Aileen Clarke
Published: over 6 years ago

Software Mentions 2